Featured Article

Treating asthma and COPD (chronic bronchitis and emphysema) effectively can be a difficult task for physicians and patients alike. But with the advent of Fasenra, a new biologic drug, asthma and COPD sufferers may find relief.

Fasenra is a monoclonal antibody that targets and binds to interleukin-5 (IL-5) receptor alpha (IL-5Ra). This allows the drug to inhibit IL-5-dependent pathways, decreasing airway inflammation and helping to reduce asthma and COPD symptoms.

What makes Fasenra a particularly beneficial treatment for these conditions is that it has fewer side effects than other treatments. According to several studies on the drug, side effects are usually minor and don’t usually flare up until a few days after administration. These side effects can include fever, headache, nausea, and coughing.

Fasenra also typically works faster than other treatments, providing relief in as little as two weeks with some patients noting results in as little as three days. It is important to note, however, that every patient responds differently to the drug, so it is important to speak to a doctor and